Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02087085 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
A Phase 2 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 310
- Enrollment target
NCT02087085 is a Phase 2 study that was terminated before completion, run by Allergan. The registered enrollment target is 310 participants.
The verdict
NCT02087085, a Phase 2 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 310 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of the brimonidine intravitreal implant in participants with geographic atrophy due to age-related macular degeneration.
Interventions
- OTHER Sham
- DRUG 400 µg Brimonidine Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2014-05-09 |
| Est. Completion | 2018-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02087085
The ClinicalTrials.gov registry entry for NCT02087085 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT02087085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02087085 about?
NCT02087085 is a clinical study titled "A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration". This study will assess the safety and efficacy of the brimonidine intravitreal implant in participants with geographic atrophy due to age-related macular degeneration.
What is the current status of trial NCT02087085?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 310 participants. The study started on 2014-05-09. Estimated completion is 2018-03-30.
What interventions are being tested in trial NCT02087085?
The interventions under investigation include: Sham (OTHER), 400 µg Brimonidine Implant (DRUG).
Who is sponsoring clinical trial NCT02087085?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.